Partnership between MRC Technology and Alzheimer’s Association will focus on finding new ways to translate fundamental research findings into new medicines that manage and treat Alzheimer’s disease.20 January 2016
MRC Technology has launched a Call for Diagnostics. It is seeking academic and industry collaborators to develop diagnostic tests in areas of unmet patient needs.28 October 2015
MRC Technology strengthens its collaborative relationships in Scandinavia
MRC Technology (MRCT) and the University of Turku (UTU, Finland) have signed a memorandum of understanding outlining how they will work together to translate biological and medical research from UTU into new therapeutics and diagnostics. UTU researchers have considerable expertise in molecular biosciences, cardiovascular and metabolic research, with particular strengths in diagnostic development and antibody technologies. UTU’s research expertise shares synergy with MRCT’s collaborative diagnostic and therapeutic discovery programmes, which help progress early-stage academic projects towards the clinic. Through this agreement, MRCT and UTU aim to combine their capabilities to move promising medical research forward into viable and accessible diagnostics and patient treatments.21 October 2015
The Dementia Consortium, a unique charity-private partnership, today announced Astex Pharmaceuticals (Astex) as a new member.12 October 2015
MRC Technology and the University of Lausanne are collaborating to find new drug treatments for diffuse large B cell lymphoma, the most common type of non-Hodgkin lymphoma.24 September 2015
EU Consortium receives funding for detection and prevention of diseases associated with ageing
Marie Skłodowska-Curie actions has awarded €2,887,054.24 to an EU consortium, including MRC Technology, to provide training for 11 young researchers in innovative therapeutic strategies. EVOluTION, the European Vascular Interventions and Therapeutic Innovation Network, aims to find novel approaches to manage chronic vascular and metabolic diseases affecting the increasing ageing population, focusing on early detection and prevention.
MRC Technology will receive €273,287.88 and the project starts 1 April 2016.
Further information http://cordis.europa.eu/project/rcn/198271_en.html17 September 2015
A project to identify new agents capable of stimulating clearance of a protein that forms aggregates in neurons of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD) has received funding worth £305,000 from the Dementia Consortium.14 September 2015
Read David Pardoe’s blog at SNA Bogados on how a collaborative approach to technology transfer and a pooling of resources can accelerate research towards the patient.8 September 2015
Georg-August-University Göttingen, Universitätsmedizin and MRC Technology collaborate to develop new therapy for neurodegenerative diseases
Georg-August-University Göttingen (UMG) and MRC Technology (MRCT) have signed a collaboration agreement for the development of a novel therapy for neurodegenerative diseases based on an antibody that targets particular forms of amyloid beta peptides, amyloid beta 4-x. The aim is to develop a new antibody therapy for Alzheimer’s Disease (AD).28 July 2015
BIA’s report, Celebrating UK bioscience, features UK bioscience successes. It incldes Keytruda, a new generation drug which uses the body’s immune system to fight cancer. It features MRC Technology’s role humanising the antibody. Read the article.27 July 2015